Although eIF3e silencing results in HR defect also in breast cancer cells (Supplementary Figure 1), we found that these eIF3e-depleted cells were not sensitive to veliparib treatment, in contrast to BRCA1-depleted cells (Figure 1A). The gene discussed is EIF3E; the disease is breast carcinoma.